United States: Bayer Secures Major Settlement in Long-Running Roundup Cancer Dispute
A major legal battle involving one of the world's most widely used weedkillers has reached a significant turning point in the United States. A Missouri judge has approved a settlement worth up to $7.25 billion involving Bayer and thousands of people who allege that exposure to its Roundup herbicide contributed to the development of cancer.
The decision, issued on Friday, November 20, 2026, establishes a compensation framework intended to resolve a substantial portion of existing and future claims linked to non-Hodgkin lymphoma, a type of blood cancer. For Bayer, the agreement represents an important opportunity to reduce the financial and legal uncertainty that has surrounded its acquisition of Monsanto.
A Compensation Framework Extending Over Two Decades
Under the approved arrangement, Bayer will contribute funds to a dedicated compensation mechanism over a period of up to 21 years. The total commitment could reach $7.25 billion, with payments distributed according to individual circumstances.
Compensation is expected to vary considerably, with estimated individual awards ranging from approximately $10,000 to $165,000. Several factors will determine the amounts, including the age at diagnosis, the severity of the illness and the duration and nature of exposure to Roundup.
The agreement covers people already diagnosed with non-Hodgkin lymphoma as well as certain individuals who may develop the disease in the future following previous exposure.
Missouri Circuit Judge Timothy Boyer considered the proposed framework acceptable, describing its financial provisions as fair and adequate. He also emphasized the risk that rejecting the agreement could prolong legal proceedings and delay compensation for seriously ill claimants.
Bayer Seeks to Contain the Consequences of the Monsanto Acquisition
The legal controversy dates back several years and became a major challenge for Bayer after its $63 billion acquisition of Monsanto in 2018.
Monsanto introduced Roundup in 1974, with glyphosate as its principal active ingredient. The herbicide subsequently became a widely used agricultural product, valued for its effectiveness in controlling weeds in farming operations, gardens and residential areas.
Following the acquisition, Bayer inherited thousands of lawsuits from consumers, agricultural workers and other individuals who claimed that prolonged exposure to the product contributed to their cancer diagnoses.
The company has faced approximately 200,000 claims over the years. Although it previously committed substantial sums to resolve litigation, the continued arrival of new cases maintained pressure on its financial position and corporate strategy.
The newly approved agreement is designed to address a significant portion of that exposure and provide greater predictability for the company's future legal obligations.
Scientific Disagreement Remains at the Heart of the Controversy
Despite the financial agreement, the scientific debate surrounding glyphosate has not been definitively settled.
In 2015, the International Agency for Research on Cancer, part of the World Health Organization, classified glyphosate as probably carcinogenic to humans. By contrast, the US Environmental Protection Agency has maintained that the chemical is unlikely to cause cancer when used according to instructions.
Bayer continues to reject allegations that Roundup causes cancer, defending the product's safety and referring to regulatory assessments and scientific research.
These conflicting positions have contributed to the complexity of the litigation, with courts examining questions of scientific evidence, product warnings and manufacturers' legal responsibilities.
Legal Challenges Could Continue Despite the Agreement
The settlement represents substantial progress for Bayer, but it does not necessarily bring every Roundup-related dispute to an end. Some claims remain outside the agreement, while disagreements over compensation levels and the rights of future claimants have generated criticism from certain legal representatives.
The approval also follows a significant development at the US Supreme Court in June 2026, when justices limited the ability of plaintiffs to pursue certain state-level claims alleging inadequate cancer warnings on Roundup packaging.
For Bayer, the combination of the settlement and the evolving legal environment could substantially reduce exposure to future litigation. Nevertheless, the possibility of an appeal means that the agreement's long-term implications will continue to attract attention.
Ultimately, the case highlights the growing financial and regulatory consequences facing multinational chemical manufacturers when questions arise over the safety of widely distributed agricultural products.
-
17:00
-
16:30
-
16:00
-
15:30
-
15:00
-
14:58
-
14:39
-
14:32
-
14:30
-
14:25
-
14:21
-
14:15
-
14:10
-
14:03
-
14:00
-
13:56
-
13:55
-
13:30
-
13:00
-
12:45
-
12:30
-
12:15
-
12:00
-
11:45
-
11:30
-
11:18
-
11:15
-
11:00
-
10:45
-
10:30
-
10:15
-
10:00
-
09:45
-
09:30
-
09:15
-
09:00
-
08:44
-
08:20
-
00:30
-
23:00
-
22:30
-
22:00
-
21:30
-
21:00
-
20:30
-
20:00
-
19:30
-
19:00
-
18:30
-
18:00
-
17:45
-
17:30